Form 4: Gilead Sciences CEO Exercises Stock Options and Sells Shares

Gilead Sciences CEO, Daniel P. O'Day, exercised stock options and sold a portion of the acquired shares on December 10, 2024.

Summary

• Gilead Sciences CEO, Daniel P. O'Day, executed a transaction involving company stock on December 10, 2024.
• Mr. O'Day exercised 10,295 restricted stock units, which converted into common stock.
• Following the exercise, Mr. O'Day sold 4,762 shares of common stock at a price of $92.34 per share.
• After these transactions, Mr. O'Day directly owns 501,528 shares of Gilead Sciences common stock.
• The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 6.25% vesting quarterly thereafter.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. It's a neutral event.

Industry Context

This is a routine filing related to executive stock transactions and is common practice for publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, and the reporting of these transactions via SEC Form 4 is standard practice.
• The vesting schedule of the restricted stock units, with a four-year vesting period and quarterly vesting after the first year, is a typical structure for executive compensation packages.
• Companies like Amgen, AbbVie, and Biogen also have similar reporting requirements for their executives' stock transactions.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive stock activity.
• The sale of shares by the CEO could have a minor impact on the stock price, but it is unlikely to be significant given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Gilead Sciences, stock options, insider trading, SEC Form 4, Daniel P. O'Day, restricted stock units, stock sale